c-Met positive Adenocarcinoma of Esophagus

The main purpose of the Phase I (Phase Ib dose escalation phase) study is to evaluate the safety and tolerability of RC108 combined with Teplizumab in patients with advanced solid tumors expressing c-Met. To determine the Phase II recommended dose (RP2D) and/or maximum tolerated dose (MTD) of RC108 combined with Teplizumab in patients with advanced solid tumors expressing c-Met. The main purpose of the Phase II (Phase II dose expansion phase) study is to evaluate the efficacy and safety of RC108 combined with Teplizumab in patients with advanced solid tumors expressing c-Met (including but not limited to adenoid cystic carcinoma, digestive system malignancies, head and neck squamous cell carcinoma, non-small cell lung cancer, clear cell or papillary renal cell carcinoma, triple-negative breast cancer, ovarian cancer, castration-resistant prostate cancer, thyroid cancer and other cancers that may benefit).

Phase Ib: To evaluate the tolerability, safety, and RP2D of SCC244 in patients with locally advanced and metastatic non-small cell lung cancer (including pulmonary sarcomatoid carcinoma) with MET exon 14 skipping or MET expansion (GCN≥5), MET protein overexpression (IHC 3+), and previous standard treatment failure (platinum-containing chemotherapy regimen), chemotherapy intolerance, or inappropriate chemotherapy. Phase II: To evaluate the anti-tumor activity of SCC244 in patients with advanced non-small cell lung cancer (NSCLC) with MET exon 14 skipping.

Primary Objectives: - The primary objective of this study is to determine the overall response rate (ORR) of telisotuzumab vedotin in c-Met+ NSCLC subjects. Secondary Objectives Secondary objectives are to determine: - Duration of response (DoR) - Disease control rate (DCR) - Duration of disease control (DDC) - Progression-free survival (PFS) - Overall survival (OS) - Safety and tolerability